|Articles|January 10, 2011

CoreLab Partners Launches Imaging Application

CoreLab Partners, Inc has launched a new advanced imaging application named ImagEngine.®

The ImagEngine® system is a software program which will be utilized exclusively by CoreLab Partners’ board-certified Radiologists to calibrate, read, annotate, and review digitized medical images. This advancement is an integral component of a technological suite of solutions to enhance productivity, improve quality, and accelerate timelines.

Various elements of the staged roll-outs will include:

The ability to load and display DICOM images, associated measurement and calibration objects

Segmentation tools

Registration tools to support multi-modality fusion with synchronized scrolling and lesion propagation

Registration of multi-modality voxel volumes

Calculates geometric and intensity based statistics

Object tagging with meta-data such as user ID, anatomical site code and label

Full integration with CoreLab Partners’ information flow, repository and Oracle Clinical database

Support for centralized storage and retrieval of application configuration information based on project protocol.

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related to this article

September 25th, 2026

Sponsor Oversight in an Outsourced Trial: What Good Looks Like and How to Evidence It

Sponsor oversight of outsourced CRO work is often robust in practice but fails inspection because oversight decisions are fragmented across systems and lack an audit trail, requiring sponsors to document oversight as a connected operating system with clear decision records, escalation pathways, and issue resolution from start to finish.

September 25th, 2026

How AI Is Changing Endpoint Selection Before a Trial Even Starts

In this video interview, Claire Riches, VP of clinical solutions at Citeline, explains how AI is expanding endpoint selection beyond the bounded experience of a single sponsor team—and surfacing options that traditional design thinking might never have considered.

September 25th, 2026

ACT Brief: Patient-Site Trust Barriers, Rare Disease Evidence Without Registry, and RWD Enrollment Accuracy

In today's ACT Brief, we examine what patient-site relationships need beyond easier technology, how to build defensible rare disease evidence from scratch, and how real-world data and AI improve enrollment screening accuracy.

© putilov_denis - © putilov_denis - stock.adobe.com

September 24th, 2026

When There’s No Registry: Building Rare Disease Evidence That Supports Regulatory Scrutiny

In rare disease drug development where no registry or natural history dataset exists, real-world evidence quality depends on treating evidence engineering as a design-stage decision, defining intended regulatory use and standardizing endpoints, harmonization, and data provenance upfront rather than reconciling gaps after collection.

September 24th, 2026

Trust, Technology, and the Patient-Site Relationship: Q&A with Andrea Valente, uMotif

In this Q&A, Andrea Valente, CEO of uMotif, discusses what it takes to build genuine trust between patients and sites, why making technology easier to use isn't the same as making patient-site interaction more effective, and where the industry is still falling short in its push toward patient-centered trial design.

September 24th, 2026

ACT Brief: Data Provenance and Device Strategy, Cell-Gene Therapy Site Readiness, and Data Harmonization Bottleneck

In today's ACT Brief, we examine why defensible trial data depends on traceability and platform ownership, what CGT site readiness requires as therapy moves to community care, and why data harmonization is AI's primary bottleneck.

September 23rd, 2026

Clinical Site Readiness for Cell and Gene Therapies: Operational and Supply Chain Challenges as they Scale and as they Expand into the Community Care Setting

Cell and gene therapy access expands into community care settings only when operational coordination, site readiness, and supply chain standardization become first-order priorities equivalent to manufacturing capacity, requiring standardized processes, digital integration, and distributed logistics networks.

September 23rd, 2026

Beyond Compliance: Vivalink's Cecilia Xi, PhD, on Data Provenance and Sustainable Device Strategy in Clinical Trials

In this episode of Beyond Compliance, Otis Johnson, PhD, MPA, founder and principal consultant at Vantix Operations, speaks with Cecilia Xi, PhD, VP of clinical and scientific affairs at Vivalink, about why defensible trial data depends on traceability, platform ownership, and device strategy long after a study ends.

CoreLab Partners Launches Imaging Application

Related to this article

Trending on Applied Clinical Trials Online

When There’s No Registry: Building Rare Disease Evidence That Supports Regulatory Scrutiny

Sponsor Oversight in an Outsourced Trial: What Good Looks Like and How to Evidence It

How AI Is Changing Endpoint Selection Before a Trial Even Starts

How to recruit specialty volunteer populations for early-phase clinical research: 5 things to ask when choosing a CRO partner

Beyond Compliance: Vivalink's Cecilia Xi, PhD, on Data Provenance and Sustainable Device Strategy in Clinical Trials